TG40.F Oxurion NV
- Market cap
- EUR 46.4K
- P/E
- 0.0x
- P/B
- 5.73x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is TG40.F undervalued?
Graham numberThe Graham number of Oxurion NV cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Oxurion NV fundamental analysis
No fundamental analysis for Oxurion NV yet.
Oxurion NV stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Oxurion NV
Oxurion NV, a biopharmaceutical company, develops medicines for vascular retinal disorder in Belgium. The company is developing ophthalmic treatments to preserve vision for patients geographic atrophy and wet age-related macular degeneration. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.
Full company profileOxurion NV financial statements
Oxurion NV annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 1.13M | 595K | 263K | 3.00K | 555K |
| Gross Profit | 516K | 82.0K | 104K | -40.0K | 555K |
| Operating Income | -27.4M | -21.9M | -12.0M | 382K | -3.28M |
| EBITDA | - | -30.3M | -18.6M | 278K | -3.62M |
| Net Income | -29.2M | -31.7M | -19.0M | 119K | -3.73M |
| EPS | -7,465 | -771 | -54 | 0.04 | -0.06 |
| Balance Sheet | |||||
| Total Assets | 18.9M | 12.0M | 6.55M | 5.70M | 3.83M |
| Total Liabilities | 20.0M | 16.6M | 19.7M | 16.8M | 16.5M |
| Shareholders' Equity | -1.08M | -4.58M | -13.2M | -11.1M | -12.9M |
| Cash & Short-term Investments | 9.74M | 3.50M | 1.62M | 455K | 430K |
| Cash Flow | |||||
| Operating Cash Flow | -27.0M | -19.4M | -9.77M | -2.07M | -1.71M |
| Capital Expenditure | 32.0K | 59.0K | 1.00K | 0.00 | 0.00 |
| Free Cash Flow | -27.0M | -19.4M | -9.77M | -2.07M | -1.71M |
| Ratios | |||||
| ROA | -154.5% | -264.2% | -289.6% | 2.1% | -97.5% |
| Net Profit Margin | -2,584.9% | -5,325.2% | -7,212.5% | 3,966.7% | -671.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Oxurion NV dividends
Oxurion NV has not paid dividends in the last 8 fiscal years.
Last stock split: 1:10000 on Sep 3, 2024.
Who owns Oxurion NV
- Insiders 25.53%
- Institutions 0.00%
- Public & others 74.47%
- Shares outstanding 232M
- Free float 55.6M
Oxurion NV company profile
- Company name
- Oxurion NV
- Ticker
- TG40.F
- ISIN
- BE0974487192
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 26
- Fiscal year end
- December
- Address
- Gaston Geenslaan 1, Leuven, Belgium, 3001
- Phone
- 32 1 675 13 10
- Website
- oxurion.com
About Oxurion NV
Oxurion NV, a biopharmaceutical company, develops medicines for vascular retinal disorder in Belgium. The company is developing ophthalmic treatments to preserve vision for patients geographic atrophy and wet age-related macular degeneration. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.
Oxurion NV management
1- Mr. Pascal GhosonCEO, CFO & Executive Director · born 1989